why choose us

First received: March 16, 2023

Clinical Trial: Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma in Patients Undergoing Craniotomy

Study Status: Completed

Recruit Status: RECRUITING

Condition: Recurrent Glioblastoma

Study Type: INTERVENTIONAL


Official Title: Phase 1, Dose Escalation, Non-Randomized, Open Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells (AMSCs) for Recurrent Glioblasto

Brief Summary: This phase I trial tests the safety, side effects, and best dose of allogenic adipose-derived mesenchymal stem cells (AMSCs) in treating patients with glioblastoma that has come back (recurrent) who are undergoing brain surgery (craniotomy).Glioblastoma is the most common and most aggressive form of primary and malignant tumor of the brain.Currently, the standard of care for this disease includes surgical resection, followed by radiation with chemotherapy and tumor treating fields.Despite this aggressive therapy,…

Read more